Anju Welcomes Atherion Bioresearch as the Newest CRO Partner
Anju has announced a strategic partnership with Atherion Bioresearch, a full-service CRO. This collaboration provides both organizations opportunities to accelerate growth, streamline processes, and enhance data integrity.
Atherion Bioresearch selected Anju as a preferred partner due to Anju's eClinical solutions, industry knowledge, and their shared dedication to advancing the field of clinical research. Atherion possesses capabilities in diagnostics and therapeutics, as well as drug chemistry and manufacturing.
"This is a monumental step forward," said Michael Rosol, CEO at Atherion Bioresearch in a press release. "We are thrilled to combine our strengths and leverage Anju's cutting-edge solutions. This partnership will empower us to deliver even more efficient, compliant, and patient-centric clinical trials."
Paul Sahargun, SVP of eClinical at Anju, commented in a press release, "We look forward to this new partnership with Atherion. Through our combined resources we can redefine the standard for data integrity, operational efficiency, and patient-focused clinical trials."
Anju will serve Atherion in the advancement of therapeutic and diagnostic trials, including those focused on radiotherapeutics and in indications including oncology, inflammation and immunology, respiratory medicine, and ophthalmology.
Reference
Anju Welcomes Atherion Bioresearch as the Newest CRO Partner. (2023, October 31). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
